Vertex Pharmaceuticals has delivered significant shareholder value over the past half-decade, outperforming the market by 8.53% on an annualized basis. The company generated an average annual return of 19.73% during this period, highlighting the impact of compounded returns on long-term investment growth. Currently, Vertex Pharmaceuticals holds a market capitalization of $125.63 billion.

Investment Growth Analysis

The performance of Vertex Pharmaceuticals stock over the last five years illustrates the potential for wealth creation through consistent market outperformance. Investors who allocated capital to the stock five years ago have seen substantial appreciation in their holdings.

Hypothetical Investment Returns

The following table details the growth of a hypothetical investment in Vertex Pharmaceuticals over the specified period:

The key insight from this data is the significant difference compounded returns can make to cash growth over an extended period. With a current share price of $494.99, the stock has multiplied the value of initial investments made five years ago.

Vertex Pharmaceuticals has generated significant shareholder value over the last decade, outperforming the broader market by an average of 3.68% annually. The company delivered an average annual return of 17.28% during this period, highlighting the impact of compounded growth on long-term investments. Currently, Vertex Pharmaceuticals maintains a market capitalization of $112.92 billion.

The performance data illustrates how consistent returns can accumulate over time. Investors who allocated capital to the stock ten years ago have seen substantial appreciation in their holdings.

Investment Growth Analysis

The following table details the growth of a hypothetical investment in Vertex Pharmaceuticals over the past decade:

The primary takeaway from this data is the material effect that compounded returns have on wealth creation over extended periods. While past performance is not indicative of future results, the historical trajectory demonstrates the potential for equity appreciation in the biopharmaceutical sector.